Biogen initiates Phase 3 pediatric study of Omaveloxolone for treatment of Friedreich Ataxia
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
BRAVE study will explore the potential of omaveloxolone to address the critical unmet need of the pediatric FA population
SUP will obtain regulatory approvals for selling Tiotropium DPI in China
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Now approved for both acute and chronic HCV in adults and children aged 3 and above
The partnership combines Boehringer’s expertise in canine cardiology with Eko’s digital stethoscopes and AI algorithms
Enflosina is a long-acting monoclonal antibody that provides direct protection for up to 5 months
Subscribe To Our Newsletter & Stay Updated